BioMarin (BMRN) Target Goes to $85 at Nomura on VIMIZIM Approval
Tweet Send to a Friend
Nomura Securities analyst M. Ian Somaiya raised his price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from $75 to $85 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
